Shares of Beta Bionics Inc. (NASDAQ: BBNX) surged 19.44% in after-hours trading on Tuesday following the release of its third-quarter 2025 financial results, which exceeded analyst expectations and prompted the company to raise its full-year guidance.
The medical device company, known for its iLet Bionic Pancreas System, reported a quarterly loss of $0.33 per share, significantly beating the analyst consensus estimate of a $0.44 loss. This represents a 77.4% improvement from the $1.46 loss per share reported in the same quarter last year. Revenue for Q3 2025 came in at $27.3 million, surpassing analyst projections of $23.97 million and marking a robust 63.14% increase from $16.7 million in the prior-year period.
Beta Bionics' strong performance was driven by impressive growth across its sales channels. The company's Durable Medical Equipment (DME) channel net sales reached $21.0 million, up from $14.5 million in the same quarter last year. Meanwhile, the Pharmacy Benefit Plan (PBP) channel saw substantial growth, with net sales climbing to $6.2 million from $2.2 million in Q3 2024. In light of these results, Beta Bionics raised its full-year 2025 revenue guidance to over $96.5 million, up from the previous range of $88 million to $93 million. The company also increased its estimated gross margin forecast for the year to 54-55%, up from the prior range of 52-55%.
Adding to the positive momentum, Beta Bionics announced that it received Special 510(k) clearance from the FDA on September 29, 2025, for updates to its iLet device. This regulatory milestone is expected to further strengthen the company's market position in the diabetes management space. The combination of strong financial performance, raised guidance, and product advancements appears to have fueled investor enthusiasm, resulting in the significant after-hours stock price surge.
Comments